MBC

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Retrieved on: 
Tuesday, March 19, 2024
HER2, Acute leukemia, Exercise, Index, Exchange, Colorectal cancer, MMR, Memorial, Headache, Patient, Research, Diarrhea, Brain, CML, KOL, Aes, Sale, Cancer, Security (finance), IND, MBA, Prospectus, MBC, Nausea, Therapy, CRC, PIPE, Pharmacokinetics, MTD, Food, Pharmaceutical industry

BOULDER, Colo., March 19, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $90 million, before deducting offering expenses. The financing includes participation from new and existing investors, including Commodore Capital, Fairmount, Venrock Healthcare Capital Partners, a biotech investor, a large mutual fund, Rock Springs Capital, Logos Capital, Woodline Partners LP and Acuta Capital Partners.

Key Points: 
  • “The additional funding further strengthens our balance sheet and enables us to achieve critical, longer-term clinical milestones as we advance our parallel lead programs, ELVN-001 and ELVN-002.
  • Enliven anticipates the gross proceeds from the private placement to be approximately $90 million, before deducting offering expenses.
  • The PIPE financing is expected to close on or about March 21, 2024, subject to satisfaction of customary closing conditions.
  • Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, March 14, 2024
Research, U.S. FDA, Trastuzumab, Colorectal cancer, Patient, Food and Drug Administration, CML, Running, G&A, Disclosure, MBA, MBC, Therapy, Cancer, CRC, FDA, Food, Pharmaceutical industry

BOULDER, Colo., March 14, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the fourth quarter and full year ended December 31, 2023, provided updated guidance on parallel lead product candidates and highlighted pipeline progress.

Key Points: 
  • Research and development (R&D) expenses: R&D expenses were $17.9 million for the fourth quarter of 2023, compared to $8.2 million for the fourth quarter of 2022.
  • General and administrative (G&A) expenses: G&A expenses for the fourth quarter of 2023 were $4.8 million, compared to $2.0 million for the fourth quarter of 2022.
  • Net Loss: Enliven reported a net loss of $19.4 million for the fourth quarter of 2023, compared to a net loss of $9.6 million for the fourth quarter of 2022.
  • Total net loss for the full year 2023 was $71.6 million, compared to $37.7 million for the full year 2022.

MasterBrand Adds Patrick Shannon to Board of Directors

Retrieved on: 
Wednesday, March 27, 2024
Home Goods, Construction & Property, Other Manufacturing, Other Construction & Property, Interior Design, Manufacturing, Retail, Residential Building & Real Estate, Certified Public Accountant, University, Senior, MBA, MBC, AGCO, BBA, Mercer University, Allegion, Arthur Andersen, Management

MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced that Patrick Shannon was appointed to the Company’s Board of Directors effective immediately.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced that Patrick Shannon was appointed to the Company’s Board of Directors effective immediately.
  • “Patrick is a seasoned executive with extensive financial leadership experience and a track record of operational excellence,” said Dave Banyard, President and Chief Executive Officer.
  • Mr. Shannon has served on the board of directors of Astec Industries since 2024.
  • Mr. Shannon holds a BBA in accounting from the University of Georgia and an MBA from Mercer University.

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Retrieved on: 
Tuesday, March 5, 2024
MBC, Autoimmune disease, Safety, ASX, Observation, Paclitaxel, Patient, Disease, IMM, Cancer, Pharmaceutical industry

Updated safety data from patients with HR-positive/HER2-negative/low metastatic breast cancer (MBC) treated with this innovative immuno-oncology (IO)-chemotherapy combination reveal no treatment-emergent serious adverse events.

Key Points: 
  • Updated safety data from patients with HR-positive/HER2-negative/low metastatic breast cancer (MBC) treated with this innovative immuno-oncology (IO)-chemotherapy combination reveal no treatment-emergent serious adverse events.
  • Additionally, all treatment-emergent adverse events during the safety observation period to date have been of mild severity.
  • The biologically active 30mg efti dose, previously the highest dose of efti ever tested, has demonstrated a stronger immune response and greater efficacy than lower dosing levels (1mg, 6mg) in multiple clinical trials.
  • The ongoing randomized Phase II portion of the trial, which will include up to 58 evaluable patients, is focused on whether 90mg efti dosing is safe and more efficacious than 30mg dosing.

New Study Addressing Global Concern for Breast Cancer Treatment Now Available in Clifton, N.J.

Retrieved on: 
Monday, March 4, 2024
Research, Pharmaceutical, Oncology, Consumer, Hospitals, Genetics, Clinical Trials, Science, Women, Seniors, FDA, Practice Management, Health, Quality of life, AstraZeneca, MBC, Mutation, ESR1, Patient, Birth control

A cancer research study focusing on hormone receptor-positive HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is now available to patients in the Clifton, N.J., area.

Key Points: 
  • A cancer research study focusing on hormone receptor-positive HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is now available to patients in the Clifton, N.J., area.
  • The SERENA-6 trial, sponsored by AstraZeneca, is a global study that aims to address a critical issue faced by many patients: their treatments become less effective over time.
  • In advanced breast cancer, patients receive a treatment that combines an estrogen-reducing drug with a drug that slows cancer cell growth.
  • This study will evaluate if an experimental trial drug, combined with a cancer-slowing drug, might work better than conventional estrogen-reducing drugs for patients with ESR1 mutations.

Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth

Retrieved on: 
Thursday, February 29, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, NSCLC, Acquisition, Breast cancer, Head, Recurrence, Boshoff, CREST, MBC, Encorafenib, Growth, HR, Spacecraft, PFE, Prostate, Metastasis, Pembrolizumab, Lung, ADC, Monoclonal antibody, Webcast, Patient, Lymphoma, Multiple myeloma, Brentuximab vedotin, PD-L1, Cancer, Fine chemical

A replay of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www.pfizer.com/investors .

Key Points: 
  • A replay of the webcast and related materials, including the presentations and a summary and transcript, will be made available on the Pfizer investor relations website at www.pfizer.com/investors .
  • “With the completion of the Seagen acquisition in 2023, Pfizer has significantly expanded its Oncology organization to amplify its efforts to advance new standards of care and improve outcomes for patients,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.
  • Pfizer’s Oncology portfolio is focused on three core scientific modalities: small molecules, antibody drug conjugates (ADCs), and bispecific antibodies, including other immuno-oncology biologics.
  • Please read full Prescribing Information , including BOXED WARNING, for ELREXFIOTM (elranatamab-bcmm).

MasterBrand Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, February 26, 2024
Manufacturing, Interior Design, Other Manufacturing, Residential Building & Real Estate, Construction & Property, MBC, Forecasting, Investment, Culture, Growth, GAAP, Webcast, Tax, Public expenditure, EPS, Security, Depreciation, Video game

MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced fourth quarter and full year 2023 financial results.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced fourth quarter and full year 2023 financial results.
  • Net sales were $677.1 million, compared to $784.4 million in the fourth quarter of 2022, primarily due to lower volumes, driven by softer end-market demand.
  • Adjusted EBITDA1 was $85.8 million, compared to $97.8 million in the fourth quarter of 2022.
  • During the fourth quarter and full year 2023, the Company repurchased approximately 527 thousand shares of common stock and approximately 1.9 million shares of common stock, respectively.

Sermonix Pharmaceuticals Announces MBC Alliance Membership, New ‘Discover ELAINE’ Website

Retrieved on: 
Monday, February 12, 2024
Eli Lilly, Therapy, Breast cancer, Fulvestrant, Neoplasm, Quality of life, MBC, Learning, Life, ESR1, Patient, Child, Mutation, Partnership

“Lasofoxifene, our lead investigational drug, has demonstrated both potential efficacy in combating metastatic breast cancer and potential benefit with respect to vaginal and sexual health.

Key Points: 
  • “Lasofoxifene, our lead investigational drug, has demonstrated both potential efficacy in combating metastatic breast cancer and potential benefit with respect to vaginal and sexual health.
  • The website and studies were named for Dr. Elaine Davidson Nemzer, the sister of Miriam Portman.
  • Davidson Nemzer was a brilliant and compassionate child psychiatrist whose life was cut short by mBC at the age of 47.
  • “It provides us with passion and purpose to help those suffering with metastatic breast cancer.”
    To learn more about Sermonix Pharmaceuticals and lasofoxifene, visit https://sermonixpharma.com .

Your Family Entertainment AG takes the next step and presses ahead with its international expansion

Retrieved on: 
Wednesday, February 7, 2024
Partnership, Family, Life, Television, YFE, RIC, WKN, Family Entertainment, Violence, MBC

Bernd Wendeln (COO Your Family Entertainment): "With these steps, we are further expanding our position as a global provider of children's and family entertainment.“

Key Points: 
  • Bernd Wendeln (COO Your Family Entertainment): "With these steps, we are further expanding our position as a global provider of children's and family entertainment.“
    Your Family Entertainment AG (“YFE”, WKN: A161N1, ISIN: DE000A161N14, ticker symbol: RTV), a leading children's and family entertainment company, announces the successful expansion of its global presence through cooperation agreements with two renowned international media companies.
  • Your Family Entertainment AG has further expanded its collaboration with MBC GROUP, the leading media company in the Middle East and North Africa.
  • Bernd Wendeln, COO of Your Family Entertainment AG: "The expansion of our partnerships with leading players in the MENA region and Mexico illustrates our continued commitment and success in making first-class, child-friendly entertainment accessible worldwide.
  • These steps further strengthen our position as a global provider of children's and family entertainment.

WEBINAR: Exploring the Impact of Measurement-Based Care at Homewood Health

Retrieved on: 
Thursday, January 25, 2024
Technology, Mental Health, Other Technology, Biotechnology, Other Health, Continuing, Training, Health, Education, MBC, Mental, Nursing

Greenspace Health and Homewood Health are excited to present an educational event, Exploring the Impact of Measurement-Based Care at Homewood Health.

Key Points: 
  • Greenspace Health and Homewood Health are excited to present an educational event, Exploring the Impact of Measurement-Based Care at Homewood Health.
  • This session aims to share the clinical outcomes of Homewood Health’s Measurement-Based Care (MBC) implementation, along with key insights that have driven care quality improvements and innovation across their mental health services.
  • The session will provide a guiding framework for other mental health organizations implementing MBC, empowering them to provide the highest quality of care to the communities they serve.
  • Homewood Health’s implementation with Greenspace Health began in 2018.